RxDoctor Payments Data

Patricia Anderson, MD

Internal Medicine · Dickinson, NDNPI 1013970532

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Astellas Pharma US Inc at 32.9% of the total. Reporting peaked in 2023 at $254 and has fallen 82.5% since, to $45 in 2025.

$439in general payments, 2019–2025

Across 29 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$144
  • Merck$74
  • Dexcom, Inc.$45
  • AstraZeneca$44
  • Lundbeck LLC$37
  • Novo Nordisk$30
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$43499%
  • Education$41%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$439 in reported general payments places this provider in the 70th percentile of 159 internal medicine providers in North Dakota.

See all internal medicine providers in North Dakota

Medicare billing

Part B allowed, 2024
$366,249
Medicare patients
482
Services billed
11,853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban203$138,001
XareltoRivaroxaban110$74,030
JardianceEmpagliflozin74$69,501
JanuviaSitagliptin Phosphate79$48,179
OzempicSemaglutide34$31,389
Breo ElliptaFluticasone/Vilanterol51$26,074
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$24,408
TradjentaLinagliptin23$23,441
Tresiba Flextouch U-100Insulin Degludec34$20,896
Fiasp FlextouchInsulin Aspart (Niacinamide)26$19,917
Lantus SolostarInsulin Glargine,hum.Rec.Anlog139$18,562
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$18,439
CreonLipase/Protease/Amylase27$18,249
Potassium Chloride563$17,859
FarxigaDapagliflozin Propanediol29$17,774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$16$58,05089 claims
MerckJanuvia, Janumet Xr$74$55,13091 claims
Novo NordiskOzempic$30$31,38934 claims
AstraZenecaFarxiga$44$17,77429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 159 internal medicine providers in North Dakota.

Other internal medicine in Dickinson

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →